中医药信息2025，Vol.42Issue(2)：52-57,6.DOI:10.19656/j.cnki.1002-2406.20250209
扶正解毒方联合免疫检查点抑制剂对气阴两虚型晚期非小细胞肺癌患者的影响
Effects of Fuzheng Jiedu Formula Combined with Immune Checkpoint Inhibitors on Patients with Advanced Non-Small Cell Lung Cancer of Qi and Yin Deficiency Type
摘要
Abstract
Objective:To observe the effects of Fuzheng Jiedu Formula combined with immune checkpoint inhibitors(camrelizumab)on immune function,lung function,quality of life,and tumor markers in patients with Qi and Yin deficiency type advanced non-small cell lung cancer(NSCLC).Methods:A total of 196 patients with Qi and Yin deficiency type advanced NSCLC meeting the inclusion criteria were randomly divided into a control group and a study group,with 98 patients in each group.Both groups received conventional chemotherapy.The control group was treated with immune checkpoint inhibitors alongside chemotherapy,while the study group was treated with Fuzheng Jiedu Formula combined with immune checkpoint inhibitors alongside chemotherapy.Each treatment cycle lasted 21 days,and both groups were treated for four cycles.Changes in immune function,lung function,quality of life(QLO-C30 scores),and serum tumor markers before and after treatment were compared between the two groups,as well as clinical efficacy and the incidence of adverse reactions.Results:Rank-sum test of ordinal data showed that the clinical efficacy and total effective rate in the study group were significantly higher than those in the control group after treatment(P<0.05).After treatment,CD3+,CD4+levels,and the CD4+/CD8+ratio decreased significantly(P<0.05),while CD8+levels increased(P<0.05)in both groups.These changes were more pronounced in the study group compared to the control group(P<0.05).Post-treatment,forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC),peak expiratory flow(PEF),and maximum voluntary ventilation(MVV)were significantly improved in both groups(P<0.05),with greater improvements observed in the study group(P<0.05).QLO-C30 scores for all dimensions significantly increased in both groups(P<0.05),with higher scores in the study group compared to the control group(P<0.05).Serum levels of carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),and vascular endothelial growth factor(VEGF)were significantly reduced in both groups(P<0.05),with a more pronounced reduction in the study group(P<0.05).The incidence of adverse reactions did not significantly differ between the two groups(P>0.05).Conclusion:Fuzheng Jiedu Formula combined with immune checkpoint inhibitors is effective in treating Qi and Yin deficiency type advanced NSCLC,significantly improving immune function,lung function,quality of life,and tumor marker levels,with high safety.关键词
非小细胞肺癌/气阴两虚型/扶正解毒方/免疫检查点抑制剂Key words
Non-small cell lung cancer/Qi and Yin deficiency type/Fuzheng Jiedu Formula/Immune checkpoint inhibitors引用本文复制引用
王振,郭宗尚,孙亚飞..扶正解毒方联合免疫检查点抑制剂对气阴两虚型晚期非小细胞肺癌患者的影响[J].中医药信息,2025,42(2):52-57,6.基金项目
河南省医学科技攻关计划项目(LHGJ20220194) （LHGJ20220194）
